Analysis of the Human Protein Atlas allowed to pinpoint CCR9 as a potential immunotherapeutic target for T-ALL [138], and analysis of GENT2 allowed to determine the specificity of CCR9 expression in normal and tumor tissue samples [83]. The gene discussed is CCR9; the disease is neoplasm.